Navigation Links
New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
Date:10/2/2007

CONCORD, Mass., Oct. 2 /PRNewswire/ -- Many studies have suggested that moderate red wine consumption is beneficial to cardiovascular health. But what if you'd like to skip the alcohol? Take heart: laboratory research, just presented at the WINEHEALTH 2007 conference in Bordeaux, France, showed that Concord grape juice stimulated an arterial relaxation effect in a similar fashion to red wine. The French researchers also reported that the Concord grape juice induced a prolonged relaxation effect that has not yet been reported with red wine.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070913/NYTH022LOGO-b )

Dr. Valerie Schini-Kerth and a team of researchers of the Universite Louis Pasteur de Strasbourg, France, found that Concord grape juice stimulated the production of nitric oxide in endothelial cells, providing a vasorelaxation effect. It is known that nitric oxide is important in the body's natural system for maintaining healthy, flexible blood vessels and helps support healthy blood pressure.

Researchers further discovered that Concord grape juice produced this relaxation effect by stimulating the same chemical reactions in the arteries that are activated by red wine. The beneficial effect provided by Concord grape juice lasted up to six hours, whereas this extended effect has not been reported with red wine. This research suggests that the benefits of drinking Concord purple grape juice may last long after finishing the juice.

This research also demonstrates that it's the components of the grape, rather than alcohol, which produce this beneficial effect for the heart.

This study supports other preliminary research in which Concord grape juice had a blood pressure-lowering effect. So, for those looking for an alternative to red wine, grape juice made from Concord grapes provides a delicious, family-friendly, heart-healthy alternative.

'/>"/>
SOURCE Welch Foods Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Inivata, a Cambridge, England -based ... the 2015 American Association for Cancer Research (AACR) Annual Meeting ... and a poster presentation. Michael Stocum , CEO ... nd . The presentation, entitled Monitoring the ... part of a session on Recent Advances in Diagnostics ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/dl9gbg/admetoxicology ) ... - Global Strategic Business Report" report to their ... for ADME-Toxicology Testing in US$ Million by the following ... The report provides separate comprehensive analytics for ... Japan , Europe , ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/vrd3bd/mammography ) has announced ... Strategic Business Report" report to their offering. ... Equipment in US$ Thousands by the following Product Segments: ... provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
Breaking Medicine Technology:Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2
... Inc. (Nasdaq: TRBN ) today announced financial results ... 30, 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) , ... , Revenue for the third quarter and nine ... $12.8 million, respectively, compared with $3.8 million and $12.2 ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at ... on Wednesday, November 11, 2009 at 10:00 a.m. PT / ... finance and chief financial officer at Amylin Pharmaceuticals, will be ... presentation will be webcast and a recording will be made ...
Cached Medicine Technology:Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 2Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 3Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 4Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 5Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 6Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 7
(Date:4/17/2015)... 18, 2015 Rosetta Radiology is proud ... out their list of diagnostic imaging services. This solidifies ... on the Upper East Side of Manhattan. , The ... capacity. The addition of PET-CT, combined with Rosetta’s state ... ability to work with patients through several stages of ...
(Date:4/17/2015)... 17, 2015 Alcohol and Violence , ... notes that drinking and driving has been the focus ... same time, the link between alcohol and crime received ... and violence and sexual assault, and their relationship to ... NCADD, 5.3 million adults in America were drinking alcohol ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 From the day ... ago, the Texas non-profit organization has empowered young people to ... effort to bring fresh water and the Gospel to ... Liberty University. Between March 17 and 27, students, faculty and ... 7,000 Liberians with fresh water and the Good News of ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Representatives Jim ... Diagnoses and Treatment Act HR 1849 in congress on ... rates and treatment for patients with the genetic disease. ... the past, would be the first to create a ... appropriate treatment of hereditary hemorrhagic telangiectasia. This would effectively ...
(Date:4/17/2015)... California (PRWEB) April 17, 2015 At ... Entertainment’s EcoLuxe Lounge and the “Salute to the Oscars” ... luxurious Beverly Hilton Hotel, overlooking the impressive Los Angeles ... were organized by Debbie Durkin, LA’s leading producer of ... Showcasing many of the world’s premier providers of eco-friendly ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2
... Calif., Feb. 12 The Centers for Disease ... heart disease is America,s leading cause of death. ... a new heart-related coronary attack, and about 470,000 ... American Heart Month, thousands of people nationwide focus ...
... West Pharmaceutical Services, Inc. (NYSE: WST ... quarter financial results before the market opens on Thursday, ... call to discuss the results and business expectations at ... please dial (888)790-3758 or (210)839-8398. The passcode is WST.A ...
... results -LAVAL, QC, Feb. 12 /PRNewswire-FirstCall/ - Labopharm Inc. ... that it will host a conference call on Thursday, ... fourth quarter 2008 financial results. Labopharm will report its ... approximately 7:00 a.m. the same day. , To access ...
... Health Coordinates North Benin Screening , ... Cotonou, Benin, ... hospital ship, the Africa Mercy, docked in Cotounou, Benin , ... nation,s Ministry of Health. , , , , ,The hospital ...
... referred to as ,male menopause, may not be a ... depression, it is estimated that four out of five ... Since 1999, re NEW MAN (renewman.com) has been renowned ... self administered testosterone and HGH (human growth hormone) treatments. ...
... Portola to Receive $75 Million Upfront Cash ... Plus Royalties on Future Sales --SOUTH SAN ... Inc., a privately-held biopharmaceutical company developing innovative ... disease, inflammatory disease and cancer, today announced ...
Cached Medicine News:Health News:The ISSA Offers 8 Tips for American Heart Month 2Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET) 2Health News:Mercy Ship Arrives in Benin 2Health News:Mercy Ship Arrives in Benin 3Health News:Male Hormone Replacement Therapy Optimism for 2009 2Health News:Male Hormone Replacement Therapy Optimism for 2009 3Health News:Male Hormone Replacement Therapy Optimism for 2009 4Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 2Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 3
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
Medicine Products: